Pieris Pharmaceuticals (PIRS) Trading Down 6%

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) fell 6% during trading on Monday . The company traded as low as $3.12 and last traded at $3.27. 529,642 shares were traded during mid-day trading, a decline of 14% from the average session volume of 615,792 shares. The stock had previously closed at $3.48.

A number of research firms have commented on PIRS. ValuEngine cut Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 10th. BidaskClub cut Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 4th. Cowen reiterated a “buy” rating on shares of Pieris Pharmaceuticals in a research note on Sunday, November 11th. Finally, HC Wainwright set a $12.00 price target on Pieris Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $10.00.

The company has a market capitalization of $188.44 million, a PE ratio of -8.18 and a beta of 1.94.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.04. Pieris Pharmaceuticals had a negative return on equity of 18.07% and a negative net margin of 17.90%. The firm had revenue of $8.35 million during the quarter, compared to analysts’ expectations of $6.16 million. As a group, research analysts anticipate that Pieris Pharmaceuticals Inc will post -0.45 earnings per share for the current fiscal year.

In other news, Director Christopher P. Kiritsy acquired 5,000 shares of Pieris Pharmaceuticals stock in a transaction dated Friday, September 14th. The stock was purchased at an average cost of $5.11 per share, for a total transaction of $25,550.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $51,100. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 5.07% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio acquired a new stake in Pieris Pharmaceuticals during the second quarter worth about $110,000. Marshall Wace LLP acquired a new stake in Pieris Pharmaceuticals during the second quarter worth about $118,000. Fox Run Management L.L.C. acquired a new stake in Pieris Pharmaceuticals during the second quarter worth about $124,000. Bowling Portfolio Management LLC acquired a new stake in Pieris Pharmaceuticals during the second quarter worth about $156,000. Finally, California Public Employees Retirement System acquired a new stake in Pieris Pharmaceuticals during the second quarter worth about $179,000. 64.85% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://sportsperspectives.com/2018/11/20/pieris-pharmaceuticals-pirs-trading-down-6.html.

About Pieris Pharmaceuticals (NASDAQ:PIRS)

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

See Also: How to calculate the annual rate of depreciation

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply